Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13507
UPID:
TRPC3_HUMAN
Alternative names:
Transient receptor protein 3
Alternative UPACC:
Q13507; A7VJS1; E9PCJ9; O00593; Q15660; Q52M35; Q5G1L5
Background:
Short transient receptor potential channel 3 (TRPC3), also known as Transient receptor protein 3, plays a crucial role in cellular functions by forming a receptor-activated non-selective calcium permeant cation channel. This channel is pivotal in various signaling pathways, activated by receptor tyrosine kinases or G-protein coupled receptors, influencing intracellular calcium levels.
Therapeutic significance:
TRPC3's involvement in Spinocerebellar ataxia 41, a disorder characterized by progressive incoordination and degeneration of the cerebellum, highlights its potential as a therapeutic target. Understanding the role of TRPC3 could open doors to potential therapeutic strategies for treating this debilitating condition.